Patents by Inventor Shuyuan Zhang
Shuyuan Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20070155008Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production with cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.Type: ApplicationFiled: August 23, 2006Publication date: July 5, 2007Applicant: INTROGEN THERAPEUTICS INC.Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho, Deborah Wilson, Lucetta Caston
-
Patent number: 7235391Abstract: The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4° C. for up to 6 months and retain an infectivity between 60–100% of the starting infectivity.Type: GrantFiled: August 28, 2001Date of Patent: June 26, 2007Assignee: Introgen Therapeutics, Inc.Inventors: Zheng Wu, Shuyuan Zhang
-
Publication number: 20070066552Abstract: Compositions and methods for preventing or inhibiting the growth of a hyperproliferative lesion in a subject that include a nucleic acid comprised in a solid or semi-solid formation or in a transdermal or transcutaneous delivery device are disclosed. Also disclosed are compositions of a nucleic acid capable of preventing or inhibiting the growth of a hyperproliferative lesion in a subject that include an adhesive. Compositions of a nucleic acid capable of preventing or inhibiting the growth of a hyperproliferative lesion in a subject that include a nucleic acid uptake enhancer are also disclosed. Methods of preventing or inhibiting the growth of a hyperproliferative lesion in a subject that involve these therapeutic compositions and devices are also disclosed.Type: ApplicationFiled: January 20, 2006Publication date: March 22, 2007Inventors: Peter Clarke, Sunil Chada, Kerstin Menander, Robert Sobol, Shuyuan Zhang
-
Publication number: 20060275781Abstract: The present invention relates to improved methods for producing adenovirus compositions wherein host cells are grown in a bioreactor and purified by size partitioning purification to provide purified adenovirus compositions.Type: ApplicationFiled: July 22, 2005Publication date: December 7, 2006Applicant: INTROGEN THERAPEUTICS INC.Inventors: Hai Pham, Shuyuan Zhang, Peter Clarke
-
Patent number: 7125706Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.Type: GrantFiled: June 12, 2001Date of Patent: October 24, 2006Assignee: Introgen Therapeutics, Inc.Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho, Shawn Gallagher
-
Publication number: 20050175592Abstract: The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4° C. for up to 6 months and retain an infectivity between 60-100% of the starting infectivity.Type: ApplicationFiled: February 18, 2005Publication date: August 11, 2005Inventors: Zheng Wu, Shuyuan Zhang
-
Publication number: 20050158283Abstract: The present invention addresses the need to improve the yield of adenovirus when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of infection temperatures lower than 37° C. in a cell culture system results in improved yields of adenovirus. In addition, it has been demonstrated that when host cells are grow in a bioreactor, initiating adenovirus infection by diluting the host cells with fresh media and adenovirus results in improved yield of adenovirus. Methods of adenoviral production and purification using infection temperatures less than 37° C. are disclosed. Methods of adenoviral production and purification wherein the host cells are grown in a bioreactor and adenovirus infection is initiated by diluting the host cells with fresh media and adenovirus are also disclosed.Type: ApplicationFiled: March 15, 2005Publication date: July 21, 2005Inventors: Shuyuan Zhang, Hai Pham
-
Publication number: 20050089999Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production witrh cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.Type: ApplicationFiled: July 30, 2004Publication date: April 28, 2005Applicant: INTROGEN THERAPEUTICS, INC.Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho, Deborah Wilson, Lucetta Caston
-
Publication number: 20040229335Abstract: The present invention addresses the need to improve the yield of adenovirus when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of infection temperatures lower than 37° C. in a cell culture system results in improved yields of adenovirus. In addition, it has been demonstrated that when host cells are grow in a bioreactor, initiating adenovirus infection by diluting the host cells with fresh media and adenovirus results in improved yield of adenovirus. Methods of adenoviral production and purification using infection temperatures less than 37° C. are disclosed. Methods of adenoviral production and purification wherein the host cells are grown in a bioreactor and adenovirus infection is initiated by diluting the host cells with fresh media and adenovirus are also disclosed.Type: ApplicationFiled: May 15, 2003Publication date: November 18, 2004Applicant: Introgen Therapeutics, Inc.Inventors: Shuyuan Zhang, Hai Pham
-
Patent number: 6726907Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production witrh cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.Type: GrantFiled: April 24, 2000Date of Patent: April 27, 2004Assignee: Introgen Therapeutics, Inc.Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho, Deborah R. Wilson, Lucetta Caston
-
Patent number: 6689600Abstract: The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4° C. for up to 6 months and retain an infectivity between 60-100% of the starting infectivity.Type: GrantFiled: November 16, 1999Date of Patent: February 10, 2004Assignee: Introgen Therapeutics, Inc.Inventors: Zheng Wu, Shuyuan Zhang
-
Publication number: 20030008375Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production witrh cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.Type: ApplicationFiled: December 27, 2001Publication date: January 9, 2003Applicant: Introgen Therapeutics, Inc.Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho
-
Publication number: 20020182723Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production witrh cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.Type: ApplicationFiled: June 12, 2001Publication date: December 5, 2002Applicant: Introgen Therapeutics, Inc.Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho, Shawn Gallagher
-
Publication number: 20020177215Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production with cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.Type: ApplicationFiled: December 27, 2001Publication date: November 28, 2002Applicant: Introgen Therapeutics, Inc.Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho
-
Publication number: 20020031527Abstract: The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4° C. for up to 6 months and retain an infectivity between 60-100% of the starting infectivity.Type: ApplicationFiled: August 28, 2001Publication date: March 14, 2002Applicant: Introgen Therapeutics, Inc.Inventors: Zheng Wu, Shuyuan Zhang
-
Patent number: 6194191Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production witrh cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.Type: GrantFiled: November 20, 1997Date of Patent: February 27, 2001Assignee: Introgen Therapeutics, Inc.Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho
-
Patent number: 5661022Abstract: A method of purifying retroviral vector particles which comprises culturing retroviral vector producer cells which are capable of generating retroviral vector particles, and obtaining a supernatant containing retroviral vector particles from the culture of retroviral vector producer cells. The supernatant is clarified, and then concentrated. The supernatant then is contacted with a precipitation agent, and the supernatant and precipitation agent are centrifuged. A precipitate is recovered, resuspended, and subjected to a high-speed centrifugation. Retroviral particles then are recovered. The above method provides for increased recovery of retroviral vector particles which may be employed in gene therapy.Type: GrantFiled: June 6, 1995Date of Patent: August 26, 1997Assignee: Genetic Therapy, Inc.Inventors: Hitoshi Kotani, Perry Newton, III, Shuyuan Zhang
-
Patent number: 5648251Abstract: The present invention relates to an efficient method, termed spin transduction, of transducing cells with retroviral vectors. Retroviral particles, suspended in a pharmaceutically acceptable carrier, are contacted with the cells to be transduced, and the mixture is centrifuged for a sufficient period of time to permit transduction. This method leads to a 3- to 15-fold increase in transduction efficiency, depending on the type of cells transduced.Type: GrantFiled: May 26, 1995Date of Patent: July 15, 1997Assignee: Genetic Therapy, Inc.Inventors: Hitoshi Kotani, Perry Newton, III, Shuyuan Zhang
-
Patent number: 5563068Abstract: A stainless steel column housing is capped with an O-ring sealed cover to form a sealed autoclavable sterile chamber. A pair of stainless steel mesh circular cylindrical concentric inner and outer columns are within the chamber. A bed of porous glass spherical beads are packed in the region between the inner and outer mesh columns. The pH and DO are monitored and controlled while culture medium is continuously supplied to and from the sterile chamber. The outer mesh column forms an outer bulk medium chamber with the housing and the inner mesh column forms an inner bulk medium chamber. A ring sparger bubbles air and CO.sub.2 mixture into the outer bulk medium chamber, the bubbles creating pressure differentials in the bulk medium chambers. These differentials cause radially bulk medium flow through the packed bead bed without pressure gradients in the bed and axial bulk medium recirculation flow in and between the inner and outer bulk medium chambers at their axial ends.Type: GrantFiled: April 21, 1994Date of Patent: October 8, 1996Assignee: Genetic Therapy, Inc.Inventors: Shuyuan Zhang, Hitoshi Kotani, Perry Newman, III